Fig. 4From: Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic ratsActivation of the survival pathway in septic rats treated with Adrecizumab. Western blot analyses of cardiac P-Akt/Akt and p62. Kruskal-Wallis test followed by Dunn’s multiple comparison test was used. *p < 0.05Back to article page